Nivolumab companion diagnostic - Dako/ONO Pharmaceutical

Drug Profile

Nivolumab companion diagnostic - Dako/ONO Pharmaceutical

Alternative Names: PD-L1 IHC 28-8 pharmDx

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Dako A/S; Ono Pharmaceutical
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Registered Malignant melanoma

Most Recent Events

  • 11 May 2016 Registered for Malignant melanoma (Diagnosis) in Europe (unspecified route)
  • 06 Apr 2016 Launched for Non-small cell lung cancer (Diagnosis) in European Union, Iceland, Liechtenstein and Norway (IV)
  • 06 Apr 2016 Registered for Non-small cell lung cancer (Diagnosis) in European Union, Iceland, Liechtenstein and Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top